Julien Torgue Scientific Director AREVA Med Since his arrival within AREVA Med in 2010, Julien prepared and filed the IND for the AREVAMED01 trial, is responsible for the clinical oversight of the ongoing clinical trial, and overseas outsourcing and preclinical partnerships.
Masahiko Tokura RIT Development Fujifilm RI Pharma Masahiko was awarded a master of science in pharmacy by the Tokyo university of science in 2007. His current focus is in the research department of Fujifilm RI pharma, where he’s mainly engaged in radiolabeling and animal studies for radioimmunotherapy. Read more...
Dragan Cicic COO & CMO Actinium Pharmaceuticals Dragan is the COO of Actinium Pharmaceuticals. He joined API from the position of Project Director of QED Technologies Inc., a life sciences strategic consulting and transactional group focused on emerging biotech, pharmaceuticals and medical devices companies. Read more...
John Babich President & CSO Molecular Insight Pharmaceuticals John serves as President and CSO. He has led the scientific and clinical development strategies since the Company’s inception. He has been an active researcher in the field of molecular imaging and targeted radionuclide therapy for the past 25 years.
John Pagel Associate Member, Clinical Research Division Fred Hutchinson Cancer Center John is Associate Professor of Medicine, Division of Oncology, University of Washington, and an Associate Member at the Fred Hutchinson Cancer Research Center. His research interests include strategies for delivering innovative targeted RIT agents to patients with hematologic malignancies. Read more...
Jason Lewis Vice Chair, Basic Research MSKCC Jason is the Vice Chair of Research, Chief of the Radiochemistry and Imaging Sciences Service, Chief Attending Radiochemist, and Director of the Radiochemistry and Imaging Probe Core in the Department of Radiology at Memorial Hospital for Cancer and Allied Diseases, as well as a Member within Memorial Sloan-Kettering Cancer Center. Read more...
Ruby Meredith Professor University of Alabama Ruby is a professor in the department of radiation oncology at the University of Alabama. Her current emphasis is using her basic science background in the development of clinical trials for cancer patients. Currently, breast cancer, non- Hodgkin’s lymphomas, and radionuclide therapy are her primary treatment areas.
Jostein Dahle CSO Nordic Nanovector Jostein is CSO at Nordic Nanovector. Previously he leader of the Radioimmunotherapy group at Institute for Cancer Research at the Norwegian Radium Hospital. He holds a Ph.D. in radiation biology from University of Oslo.
Christian Behrenbruch CEO Imaginab Christian is the Co-Founder & CEO of ImaginAb and has a decade of experience in commercializing new molecular imaging and radiopharmaceutical/targeted radiation products. ImaginAb is a clinical-stage company that specializes in re-engineering antibodies into immunoconjugates that are PK-optimized for diagnostic imaging and radiation therapy. Read more...
Christopher Pazoles Senior VP, R&D Novelos Therapeutics Christopher has over 30 years of biopharmaceutical research and development experience, he previously held senior positions at Pfizer, Abbott, Phytera and the ALS Therapy Development Institute. He holds a B.A. from Oberlin College and a Ph.D. in microbiology from the University of Notre Dame. Read more...
Ekaterina Dadachova Professor of Radiology Albert Einstein College of Medicine Kate received her Bachelor of Chemistry and PhD in Physical Chemistry degrees from Moscow State University, Moscow, Russia. She is currently a Professor of Radiology and Microbiology and Immunology and Sylvia and Robert Olnick Faculty Scholar in Cancer Research at the Albert Einstein College of Medicine in New York City.
Steven Fruchtman Senior VP & CMO Spectrum Pharmaceuticals Steve joined Spectrum in February 2011 to head clinical development. Previously, he was with Allos Therapeutics, where he was involved with the development of pralatrexate (Folotyn) and prior to that he was at Novartis.
Joseph Jurcic Professor of Clinical Medicine & Director of the Hematologic Malignancies Section MSKCC Joseph Jurcic is Professor of Clinical Medicine and Director of the Hematologic Malignancies Section at Columbia University Medical Center. He is a hematologist/medical oncologist who specializes in the treatment of leukemia. He received his medical degree from the University of Pennsylvania, completed residency in internal medicine at Barnes Hospital, Washington University School of Medicine, and received fellowship training at Memorial Sloan-Kettering Cancer Center. Read more...
Nishitha Reddy Clinician Vanderbilt-Ingram Cancer Center Nishitha is a clinical oncologist at the Vanderbilt-Ingram Cancer Center. Her focus is on treatment of lymphoma and she is an investigator on numerous clinical trials. Previously she was educated at Ambedkar Medical College, Bangalore, India.
George Sgouros Professor Johns Hopkins University George is Professor of Radiology, Oncology & Radiation Oncology, Director of Radiopharmaceutical Dosimetry Section of the Division of Nuclear Medicine, Johns Hopkins University, School of Medicine. He is chairman of the Medical Internal Radionuclide Dose Committee of the SNM. Read more...
Richard Wahl Professor Johns Hopkins University Richard is professor of radiology and nuclear medicine at John Hopkins. He is the recipient of numerous accolades and awards including the distinguished scientist award from the Academy of Molecular Imaging. His main clinical and research areas of interest are on PET/CT.
Darrell Fisher Vice Chairman MIRD Darrell leads the Isotope Sciences Program at Pacific Northwest National Laboratory - a national technology resource for scientific research on new applications of radioisotopes in science and medicine. His 38-year research experience includes development of injectable yttrium-90 radiogels and resorbable brachytherapy seeds for treating cancer. Read more...
Martin Brechbiel Senior Investigator NIH Martin joined the NCI in 1983 and received his Ph.D. from American University in 1988. He was appointed Acting Section Chief of the Radioimmune & Inorganic Chemistry Section in 1997. He became the tenured Senior Investigator and Section Chief of the Radioimmune & Inorganic Chemistry Section in 2001. Read more...
Ravi Harapanhalli Principal Consultant PAREXEL Ravi serves as the Principal Consultant and covers the consulting areas from early stages to late stages and post-approval strategies for product life cycle management. Ravi formerly served as Branch Chief in the Division of Pre-market Assessment and Manufacturing Science within the Office of New Drug Quality Assessment, CDER/FDA. Read more...
Caroline Rousseau Nuclear Medicine Department Comprehensive Cancer Center ICO Gauducheau Caroline will be presenting her latest work on the treatment of metastatic triplenegative breast cancer that cannot benefit from hormone therapy or anti-Her2/neu immunotherapy, and how Immuno-PET and RIT can help.
Bruce Freimark Director, Preclinical Development, Oncology Peregrine Pharmaceuticals Bruce has led the imaging program into a Phase 0 IND to evaluate PGN650 as a PET imaging agent for solid tumors. He joined the company in 2006 and has 24 years of experience in the pharmaceutical and biotech industry in antibody therapeutics for cancer and inflammation programs. Read more...
Steve Larson Vice Chair, Research, Department of Radiology MSKCC Steve is a nuclear medicine physician whose clinical interests focus on the use of positron emission tomography (PET) for diagnostic and molecular imaging. He also has special expertise in the care and management of patients who receive radiotargeted therapy, particularly for thyroid cancer.